Pedro Lichtinger has been appointed president and chief executive officer of BioTime’s subsidiary Asterias Biotherapeutics, which was created for the acquisition of Geron Corp.’s clinical-stage stem cell therapeutic assets. Asterias’ lead clinical programs are its AST-OPC1 cell therapeutic for spinal cord injury, and its AST-VAC2 allogeneic dendritic cell cancer immunotherapy platform.   Mr. Lichtinger has served as a director of BioTime since August 2009, where he led the field of regenerative ...